PMID- 26818795
OWN - NLM
STAT- MEDLINE
DCOM- 20160913
LR  - 20191210
IS  - 1749-8090 (Electronic)
IS  - 1749-8090 (Linking)
VI  - 11
DP  - 2016 Jan 27
TI  - The Carpentier-Edwards Perimount Magna mitral valve bioprosthesis: 
      intermediate-term efficacy and durability.
PG  - 20
LID - 10.1186/s13019-016-0412-4 [doi]
LID - 20
AB  - BACKGROUND: The Carpentier-Edwards Perimount Magna mitral valve bioprosthesis 
      (Edwards Lifesciences, Irvine, CA) is a low-profile version of the earlier 
      Perimount valve that uses the ThermaFix process for enhanced calcium removal. The 
      Magna valve has been in use since 2008, yet no publication, until now, has 
      verified its intermediate-term safety and efficacy. METHODS: From 2008 through 
      2011 (our 4-year study period), 70 Magna valves were implanted in the mitral 
      position at a single institution (the Cleveland Clinic). Echocardiograms were 
      prospectively interpreted. For this study, we reviewed patients' charts; 
      endpoints included hemodynamic measurements, in-hospital morbidity and mortality, 
      valve-related events, resource utilization, and 5-year survival rates. RESULTS: 
      The mean patient age was 68 years; 43 % of the patients had New York Heart 
      Association (NYHA) class III or IV disease, and 51.4 % had moderately severe, or 
      worse, mitral regurgitation (MR). For 43 % of the patients, the Magna valve 
      implantation was a reoperation. For 83 %, the Magna valve implantation also 
      included a concomitant cardiac procedure. The median survival rate was 4.7 years 
      and 90 % of patients were free from significant structural valve degeneration at 
      5 years. Preoperative atrial fibrillation, ischemic MR, intraaortic balloon pump 
      placement, cardiogenic shock, cardiac arrest, and renal failure were associated 
      with increased mortality. Right ventricular systolic pressure decreased from 50 
      mmHg preoperatively to 40 mmHg postoperatively, according to our matched-pair 
      analysis (P = 0.003). Per their final echocardiogram during our study period, 98 
      % of surviving patients had trivial or no MR, one patient had mild MR, and one 
      patient had severe MR. CONCLUSIONS: Our 5-year experience indicates that the 
      Magna valve offers excellent intermediate-term durability and substantial 
      echocardiographic improvement; its low-profile design make it ideal for 
      reoperations and for concomitant cardiac procedures, including valve replacement.
FAU - Loor, Gabriel
AU  - Loor G
AD  - Department of Cardiothoracic Surgery, University of Minnesota, 420 Delaware 
      Street SE, MMC 207, Minneapolis, MN, 55455, USA. gloor@umn.edu.
FAU - Schuster, Andres
AU  - Schuster A
AD  - Department of Cardiology, Cleveland Clinic, Cleveland, USA.
FAU - Cruz, Vincent
AU  - Cruz V
AD  - Lerner College of Medicine, Cleveland Clinic, Cleveland, USA.
FAU - Rafael, Aldo
AU  - Rafael A
AD  - Department of Cardiac Surgery, Baylor University Medical Center, Dallas, USA.
FAU - Stewart, William J
AU  - Stewart WJ
AD  - Department of Cardiology, Cleveland Clinic, Cleveland, USA.
FAU - Diaz, James
AU  - Diaz J
AD  - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, 
      USA.
FAU - McCurry, Kenneth
AU  - McCurry K
AD  - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, 
      USA.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20160127
PL  - England
TA  - J Cardiothorac Surg
JT  - Journal of cardiothoracic surgery
JID - 101265113
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Bioprosthesis/adverse effects
MH  - Female
MH  - *Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/instrumentation/methods
MH  - Hemodynamics/physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/*surgery
MH  - Mitral Valve Insufficiency/surgery
MH  - Prosthesis Design
MH  - Prosthesis Failure
MH  - Registries
MH  - Reoperation/instrumentation
MH  - Survival Rate
MH  - Time Factors
PMC - PMC4728780
EDAT- 2016/01/29 06:00
MHDA- 2016/09/14 06:00
PMCR- 2016/01/27
CRDT- 2016/01/29 06:00
PHST- 2015/10/21 00:00 [received]
PHST- 2016/01/12 00:00 [accepted]
PHST- 2016/01/29 06:00 [entrez]
PHST- 2016/01/29 06:00 [pubmed]
PHST- 2016/09/14 06:00 [medline]
PHST- 2016/01/27 00:00 [pmc-release]
AID - 10.1186/s13019-016-0412-4 [pii]
AID - 412 [pii]
AID - 10.1186/s13019-016-0412-4 [doi]
PST - epublish
SO  - J Cardiothorac Surg. 2016 Jan 27;11:20. doi: 10.1186/s13019-016-0412-4.